Mesenchymal stem-cell-derived exosomal miR-145 inhibits atherosclerosis by targeting JAM-A

Atherosclerosis is a chronic inflammatory disease associated with the development of plaques that can be converted into an acute clinical event by thrombosis or plaque rupture. Mesenchymal stem cells (MSCs) exhibit therapeutic effects for the treatment of various diseases, including atherosclerosis. In this study, we show that microRNA-145 (miR-145) is associated with atherosclerosis by microRNA sequencing and bioinformatics analysis. MSC-derived miR-145-rich exosomes could efficiently deliver miR-145 from MSCs to human umbilical vein endothelial cells (HUVECs). Treatment of miR-145-rich exosomes could downregulate JAM-A, inhibit migration in vitro, and reduce atherosclerotic plaque in vivo. Our study suggests that MSC-derived miR-145-rich exosomes have great potential for atherosclerosis prevention.

Automated summary

This study demonstrated that MSC-derived miR-145-rich exosomes have the potential to prevent atherosclerosis by downregulating JAM-A, inhibiting migration in vitro, and reducing atherosclerotic plaque in vivo. The findings indicate that miR-145 may play a significant role in the development and treatment of atherosclerosis.